Abstract: The present invention relates to protein-protein interactions involved in AIDS. More specifically, the present invention relates to complexes of polypeptides or polynucleotides encoding the polypeptides, fragments of the polypeptides, antibodies to the complexes, Selected Interacting Domains (SID®) which are identified due to the protein-protein interactions, methods for screening drugs for agents which modulate the interaction of proteins and pharmaceutical compositions that are capable of modulating the protein-protein interactions.

Abstract: The present invention relates to protein-protein interactions involved in AIDS. More specifically, the present invention relates to complexes of polypeptides or polynucleotides encoding the polypeptides, fragments of the polypeptides, antibodies to the complexes, Selected Interacting Domains (SID®) which are identified due to the protein-protein interactions, methods for screening drugs for agents which modulate the interaction of proteins and pharmaceutical compositions that are capable of modulating the protein-protein interactions.

Abstract: The present invention relates to protein-protein interactions involved in AIDS. More specifically, the present invention relates to complexes of polypeptides or polynucleotides encoding the polypeptides, fragments of the polypeptides, antibodies to the complexes, Selected Interacting Domains (SID®) which are identified due to the protein-protein interactions, methods for screening drugs for agents which modulate the interaction of proteins and pharmaceutical compositions that are capable of modulating the protein-protein interactions.

Abstract: The present invention relates to protein-protein interactions involved in AIDS. More specifically, the present invention relates to complexes of polypeptides or polynucleotides encoding the polypeptides, fragments of the polypeptides, antibodies to the complexes, selected Interacting Domains (SID®) which are identified due to the protein-protein interactions, methods for screening drugs of agents which modulate the interaction of proteins and pharmaceutical compositions that are capable of modulating the protein-protein interactions.

Abstract: The present invention relates to nucleic acids encoding SID® polypeptides which bind selectively to a polypeptide encoded by a pathogenic strain of the hepatitis C virus, as well as to the SID® polypeptides which are encoded by said nucleic acids. The invention also concerns vectors comprising a nucleic acid encoding a SID® polypeptide as well as host cells transformed with such vectors. The invention is also directed to two-hybrid methods which make use of the nucleic acids encoding a SID® polypeptide selected from a pathogenic strain of the hepatitis C virus as well as to methods for selecting molecules which inhibit the binding between a SID® polypeptide and a polypeptide which specifically binds thereto.

Abstract: The present invention concerns collections of recombinant cell clones derived from a prokaryotic genome, more particularly from Helicobacter pylori genome, useable for two-hybrid systems and methods to produce such collections. The invention further relates to then identification of H. pylori protein-protein interactions and to the application of said collections of recombinant cell clones and said identified proteins interactions to the pharmaceutical and diagnostic field.

Abstract: The present invention is directed to a method for selecting a prey polypeptide that is able to interact with a bait polypeptide of interest, to a prey polynucleotide encoding the prey polypeptide as well as to the prey polypeptide itself. The invention also concerns plasmids used for performing the method of the invention as well as prokaryotic or eukaryotic recombinant host organisms containing such plasmids and also a collection of said recombinant host organisms consisting in a DNA library, such as a collection of recombinant haploid Saccharomyces cerevisiae. Finally, the invention is also directed to a technical medium containing the whole information concerning the interactions between metabolically related bait and prey polypeptides and/or polynucleotides coding for bait and prey polypeptides.

Abstract: This invention relates to the detection and analysis of viral protein-protein interactions using a two-hybrid system. This invention allows the definition and use of minimal peptides involved in these protein-protein interactions. In particular, this invention relates to the use of a two-hybrid assay to screen for molecules that interact with hepatitis C virus proteins.

Abstract: Two bacterial strains deficient in endogenous adenylate cyclase activity are provided. The strains, designated BTH101 and DHM1, are useful in a signal amplification system comprising a bacterial multi-hybrid system, and more preferably a two-hybrid system, of at least two chimeric polypeptides containing a first chimeric polypeptide corresponding to a first fragment of an enzyme and a second chimeric polypeptide corresponding to a second fragment of an enzyme or a modulating substance capable of activating said enzyme as described in published PCT application WO 99/28746. The signal amplification system is useful in a method of selecting a molecule of interest, which is capable of binding to target ligand, wherein the interaction between the molecule of interest and the target ligand is detected with the signal amplification system, and the kit therefor, as described in WO 99/28746.

Abstract: The present invention relates to protein-protein interactions of adipocytes, e.g., complexes of such polypeptides, polynucleotides encoding the polypeptides and complexes thereof, fragments of the polypeptides, antibodies to the complexes, Selected Interacting Domains (SID) which are identified due to the protein-protein interactions, methods for screening drugs for agents which modulate the interaction of proteins and pharmaceutical compositions that modulate the protein-protein interactions.

Abstract: The present invention relates to protein-protein interactions involved in deafness or in hearing disorders and/or diseases. More specifically, the present invention relates to complexes of polypeptides or polynucleotides encoding the polypeptides, fragments of the polypeptides, antibodies to the complexes, Selected Interacting Domains (SID®) which are identified due to the protein-protein interactions, methods for screening drugs for agents which modulate the interaction of proteins and pharmaceutical compositions that are capable of modulating the protein-protein interactions.

Abstract: The present invention is directed to a method for selecting a prey polypeptide that is able to interact with a bait polypeptide of interest, to a prey polynucleotide encoding the prey polypeptide as well as to the prey polypeptide itself. The invention also concerns plasmids used for performing the method of the invention as well as prokaryotic or eukaryotic recombinant host organisms containing such plasmids and also a collection of said recombinant host organisms consisting in a DNA library, such as a collection of recombinant haploid Saccharomyces cerevisiae. Finally, the invention is also directed to a technical medium containing the whole information concerning the interactions between metabolically related bait and prey polypeptides and/or polynucleotides coding for bait and prey polypeptides.

Abstract: The present invention relates to protein-protein interactions between Shigella polypeptides and mammalian polypeptides. More specifically, the present invention relates to complexes of polypeptides or polynucleotides encoding the polypeptides, fragments of the polypeptides, antibodies to the complexes, Selected Interacting Domains (SID®) which are identified due to the protein-protein interactions, methods for screening drugs for agents which modulate the interaction of proteins and pharmaceutical compositions that are capable of modulating the protein-protein interactions.

Abstract: The present invention is directed to a method for selecting a prey polypeptide that is able to interact with a bait polypeptide of interest, to a prey polynucleotide encoding the prey polypepetide as well as to prey polypeptide itself. The invention also concerns plasmids used for performing the method of the invention as well as prokaryotic or eukaryotic recombinant host organisms containing such plasmids and also a collection of said recombinant host organisms consisitng in a DNA library, such as a collection of recombinant haploid Saccharomyces cerevisiae. Finally, the invention is also directed to a technical medium containing the whole information concerning the interaction between metabolically related bait and prey polypeptides and/or polynucleotides coding for bait and prey polypeptides.

Abstract: Disclosed are protein-protein interactions in adipocytes. Also disclosed are complexes of polypeptides or polynucleotides encoding the polypeptides, fragments of the polypeptides, antibodies to the complexes, Selected Interacting Domains (SID®) which are identified due to the protein-protein interactions, methods for screening drugs for agents which modulate the interaction of proteins and pharmaceutical compositions that are capable of modulating the protein-protein interactions.

Abstract: Disclosed is a technique to predict protein-protein interaction maps across organisms called an “interacting-domain profile pair” method. The method uses a high-quality protein interaction map with interaction domain information as input to predict an interaction map in another organism. It combines sequence similarity searches with clustering based on interaction patterns and interaction domain information. Results can be compared with predictions from a naive inference method based only on full-length protein sequence similarity. This domain-based method can eliminate a significant amount of false-positives compared to methods that are the consequences of multi-domain proteins; as well as increase the sensitivity by identifying new potential interactions.

Abstract: The present invention concerns collections of recombinant cell clones derived from a prokaryotic genome, more particularly from Helicobacter pylori genome, useable for two-hybrid systems and methods to produce such collections. The invention further relates to then identification of H. pylori protein-protein interactions and to the application of said collections of recombinant cell clones and said identified proteins interactions to the pharmaceutical and diagnostic field.

Abstract: The present invention relates to proteins that interaction with &bgr;TrCP. More specifically, the present invention relates to complexes of polypeptides or polynucleotides encoding the polypeptides, fragments of the polypeptides, antibodies to the complexes, Selected Interacting Domains (SID®) which are identified due to the protein-protein interactions, methods for screening drugs for agents which modulate the interaction of proteins and pharmaceutical compositions that are capable of modulating the protein-protein interactions.

Abstract: Disclosed are polypeptides named HP1122, Cj1464 and PA3351 which are the anti-&sgr;28 factor of Helicobacter pylori, Campylobacter jejuni and Pseudomonas aeruginosa, respectively and fragments and variants thereof. Also disclosed is a polypeptide named SID1122 which is the domain of Helicobacter pylori's HP1122 polypeptide involved in a specific interaction with Helicobacter pylori &sgr;28 (HP1032) and which has an anti-&sgr;28 factor activity.

Abstract: The present invention relates to nucleic acids encoding SID® polypeptides which bind selectively to a polypeptide encoded by a pathogenic strain of the hepatitis C virus, as well as to the SID® polypeptides which are encoded by said nucleic acids.